AI news impact · China A-shares

Pharmaron Beijing Co., Ltd. Class A (300759) news impact

On 2026-10-26 Wave Radar's AI rated the news on Pharmaron Beijing Co., Ltd. Class A as neutral (impact score +15%).

An industry report cited Pharmaron's 2026 H1 figures, noting new order growth exceeded 30% and CDMO new orders jumped over 50%, supported by active peptide demand.

Direction
Neutral
Impact score
+15%
Confidence
75%
Headlines read
1
Date
2026-10-26
Open 300759 news in Wave Radar

AI assessment

Media coverage reiterated strong order growth and CDMO momentum from earlier filings, offering mild positive confirmation though it is not a new corporate disclosure.

Sector impact

Reiterated robust order inflows confirm recovery momentum in CXO demand, providing mild sentiment support to medical outsourcing peers.

Headlines the AI read

Rating history

One rating per trading day the stock was covered.

More on Pharmaron Beijing Co., Ltd. Class A

300759 valuation

How the rating works

After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.